Skip to main content
Back
HROW logo

Harrow Health, Inc.

Data quality: 100%
HROW
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$34.00
▲ $0.72 (2.16%)
Mkt Cap: 1.27B
Day Range
$33.03 $34.87
52-Week Range
$20.85 $54.85
Volume
634,468
50D / 200D Avg
$44.58 / $40.45
Prev Close
$33.28

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -246.3 0.4
P/B 24.1 2.9
ROE % -8.4 3.8
Net Margin % -1.9 3.9
Rev Growth 5Y % 39.2 10.0
D/E 4.8 0.2

Analyst Price Target

Hold
$74.25 +118.4%
Low: $63.00 High: $94.00
Forward P/E
46.7
Forward EPS
$0.73
EPS Growth (est.)
+0.0%
Est. Revenue
370 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $8.79
$8.13 – $9.96
1.1 B 1
FY2029 $7.31
$6.76 – $8.28
970 M 1
FY2028 $4.13
$2.92 – $5.34
740 M 2

Key Takeaways

Revenue grew 39.22% annually over 5 years — strong growth
Debt/Equity of 4.80 — high leverage
Generating 42.98M in free cash flow
Capital efficient — spends only 0.33% of revenue on capex
Interest coverage of 1.51× — tight debt servicing

Growth

Revenue Growth (5Y)
39.22%
Revenue (1Y)36.41%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-8.42%
ROIC8.97%
Net Margin-1.89%
Op. Margin13.37%

Safety

Debt / Equity
4.80
Current Ratio2.20
Interest Coverage1.51

Valuation

P/E Ratio
-246.31
P/B Ratio24.14
EV/EBITDA39.69
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 36.41% Revenue Growth (3Y) 44.62%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 39.22% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 272.30M Net Income (TTM) -5.14M
ROE -8.42% ROA -1.29%
Gross Margin 75.05% Operating Margin 13.37%
Net Margin -1.89% Free Cash Flow (TTM) 42.98M
ROIC 8.97% FCF Growth (3Y) N/A
Safety
Debt / Equity 4.80 Current Ratio 2.20
Interest Coverage 1.51 Dividend Yield 0.00%
Valuation
P/E Ratio -246.31 P/B Ratio 24.14
P/S Ratio 4.65 PEG Ratio 4.91
EV/EBITDA 39.69 Dividend Yield 0.00%
Market Cap 1.27B Enterprise Value 1.44B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 272.30M 199.61M 130.19M 88.60M 72.48M
Net Income -5.14M -17.48M -24.41M -14.09M -18.01M
EPS (Diluted) -0.14 -0.49 -0.75 -0.51 -0.69
Gross Profit 204.37M 150.37M 90.55M 63.21M 54.26M
Operating Income 36.40M 8.82M 431,000.0 1.92M 1.61M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 399.48M 388.97M 311.76M 157.38M 98.33M
Total Liabilities 347.39M 319.67M 241.75M 130.14M 87.40M
Shareholders' Equity 52.45M 69.65M 70.36M 27.60M 11.29M
Total Debt 251.98M 228.83M 190.50M 112.23M 77.96M
Cash & Equivalents 72.93M 47.25M 74.09M 96.27M 42.17M
Current Assets 211.75M 189.65M 139.07M 118.26M 60.66M
Current Liabilities 96.30M 91.34M 49.34M 18.63M 9.72M